

1
2
3
4
5
6
7
8

National Conversation on Public Health and Chemical Exposures
Draft Monitoring Work Group Report

9
10
11
12
13
14
15
16
17
18

I. Introduction

9 The *National Conversation on Public Health and Chemical Exposures* (*National Conversation*) is a collaborative project, supported by the Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR). The *National Conversation* vision is that chemicals are used and managed in ways that are safe and healthy for all people. The project's goal is to develop an action agenda with clear, achievable recommendations that can help government agencies and other organizations strengthen their efforts to protect the public from harmful chemical exposures. The *National Conversation* Leadership Council will author the action agenda, utilizing input from six project work groups, and members of the public who choose to participate in Web dialogues and community conversations.

19 *National Conversation* work groups were formed to research and make recommendations on the following six cross-cutting public health and chemical exposures issues: monitoring, scientific understanding, policies and practices, chemical emergencies, serving communities, and education and communication. This report is the product of the Monitoring work group's deliberations. While issued to the *National Conversation* Leadership Council, the work group hopes that this report will be of value to others in a position to act on the recommendations contained herein.

26 CDC and ATSDR worked with several groups to manage the *National Conversation*, including RESOLVE, a nonprofit organization dedicated to advancing the effective use of consensus building in public decision making, the American Public Health Association (APHA), the Association of State and Territorial Health Officials (ASTHO), and the National Association of County and City Health Officials (NACCHO). These organizations and others helped ensure that a broad range of groups and individuals were engaged throughout this collaborative process, including government agencies, professional organizations, tribal groups, community and non-profit organizations, health professionals, business and industry leaders, and members of the public.

35 For more information on the *National Conversation* project, please visit
36 www.atsdr.cdc.gov/nationalconversation.

39
40

Work Group Charge, Scope, and Objectives

41 The Monitoring work group was formed to address the ongoing collection, integration, analysis, and interpretation of data about chemical use, exposure, and known and probably associated health outcomes necessary for the prevention and control of adverse health outcomes related to chemical exposures. Ongoing surveillance also provides an opportunity to evaluate the effectiveness of intervention strategies. Many federal, state, and local government bodies currently collect relevant data. The Monitoring work group was charged with analyzing current surveillance and data collection activities and recommending actions to fill data gaps, better utilize existing data, and improve coordination among the many organizations collecting relevant information. The work group addressed monitoring of chemicals in both human tissues (biomonitoring) and environmental media, including soil, air, water, consumer products, and in key built environments (e.g., schools and homes). In addition, the group addressed options for

51 better linking exposure information with health outcome data. (See Appendix A. “Monitoring Work
52 Group Final Charge.”)

53
54 *Framework for Discussion*

55 Information on chemical use, exposure pathways, exposure levels, and health outcomes is collected for a
56 variety of reasons, including regulatory, clinical, and public health purposes. To address issues related to
57 public health and chemical exposures, there is a need to better use the data already being collected, and to
58 further broaden the information that is collected. This discussion explored what a comprehensive
59 monitoring system might look like, and how we might move toward such a system.

60
61
62 **Membership**

63
64 Work groups were formed in 2009 following an open nomination process. Work group members were
65 selected based on a three stage process designed to ensure that each work group would have the capacity
66 to address and reflect different individual and organizational perspectives.¹

67
68 The skill sets and individual qualities the team chose to consider in selecting members for the Monitoring
69 work group were subject matter expertise (e.g., chemical use, environmental fate and transport,
70 biomonitoring, health surveillance, and statistics); expertise in various exposure settings and types (e.g.,
71 indoor and outdoor environments, industrial chemicals, consumer products, and pesticides); familiarity
72 with monitoring and surveillance systems; representation of those affected by exposure outcomes (e.g.,
73 community-based groups); those working to improve monitoring and surveillance systems (e.g., federal
74 agencies); and those with an understanding of privacy, ethical, and cultural issues related to data
75 collection. Furthermore, to achieve overall balance, the team sought to compose a diverse work group in
76 terms of sector, discipline, perspective, and geographic region.

77
78 John Balbus, M.D., M.P.H., senior advisor for public health, National Institute of Environmental Health
79 Sciences, chaired the Monitoring work group. Dr. Balbus was supported by Dr. Michael McGeehin,
80 CDC/ATSDR senior liaison to the Monitoring work group and director of the Division of Environmental
81 Hazards and Health Effects at CDC’s National Center for Environmental Health (NCEH); Kathy Grant, a
82 Senior Mediator at RESOLVE; and Jennifer Van Skiver, Management and Program Analyst at
83 CDC/ATSDR. Work group membership included 24 individuals with experience in the public, private,
84 and nonprofit sectors. (See Appendix B. “Monitoring Work Group Roster.”)

85
86
87 **Subgroups**

88
89 The Monitoring work group worked in three subgroups, organized to address monitoring and surveillance
90 along a temporal continuum from chemical use to health impacts. The subgroups were formed to enable
91 focused discussion of each subgroup topic. Subgroup meetings were open to all Monitoring work group
92 members, discussion notes and draft work products were circulated to all Monitoring work group
93 members, and activities of each subgroup were discussed at general work group meetings.

94
95 Chemical Use and Release Subgroup

96 The Chemical Use and Release subgroup addressed the two major themes of chemical use and release
97 monitoring and environmental monitoring.

98

¹ For additional information on the work group member selection process, see
http://www.atsdr.cdc.gov/nationalconversation/docs/membership_selection_process_report.pdf.

99 *Chemical Use and Release:* A broad examination of chemical use and release into the environment,
100 including disposal, is essential to address proactively environmental public health. Examination of
101 chemicals from the point of their use and release also is necessary for providing screening tools and for
102 assessing progress.

103
104 *Environmental Monitoring:* Monitoring of environmental media occurs through a variety of initiatives
105 carried out by local, state, and federal agencies. Knowing which chemicals are present in air, water, soil,
106 dust, food, and elsewhere is an important step in determining to which chemicals people are exposed and
107 how exposure might occur.

108 Exposure Levels Subgroup

109 The Exposure Levels, or Biomonitoring, subgroup focused on information generated by measuring
110 chemicals, their metabolites, or other markers of exposure in fluids or tissues of living organisms, to the
111 extent it was deemed relevant to humans.

112 Health Outcomes Subgroup

113
114 The Health Outcomes subgroup focused primarily on human health outcome surveillance, recognizing the
115 examination of human health outcomes as a critical component of monitoring. Surveillance of health
116 impacts is useful as a backup screening tool for sentinel health outcomes, for research linking levels of
117 exposure to specific health outcomes, and for program evaluation.

118

119

120

121

121 **Terms and Definitions**

122

123

123 *Biomarker of exposure*

124 The level of a contaminant or its metabolite collected from the body or from substances produced or
125 excreted within biological systems. In humans, this measurement can reflect the amount of the
126 contaminant that is stored in the body, and is sometimes referred to as the body burden. It indicates the
127 level of exposure (EPA, 2008a).

128

129 *Biomonitoring*

130 The assessment of exposure through direct measurement of environmental chemicals in human
131 specimens, such as blood or urine (CDC, 2009).

132

133 *Concentration*

134 The amount of a substance present in a certain amount of soil, water, air, food, blood, hair, urine, breath,
135 or any other media (ATSDR, 2009).

136

137 *Dosage/Dose*

138 1. The actual quantity of a chemical administered to an organism or to which it is exposed. 2. The amount
139 of a substance that reaches a specific tissue (e.g. the liver). 3. The amount of a substance available for
140 interaction with metabolic processes after crossing the outer boundary of an organism (EPA, 2006).

141

142 *Environmental public health surveillance*

143 Environmental public health surveillance is public health surveillance (ongoing, systematic collection,
144 analysis, and interpretation of outcome-specific data used to plan, implement, and evaluate public health
145 practice) of health effects integrated with surveillance of environmental exposures and hazards. Efforts in
146 environmental public health surveillance and this integration provide a strategic opportunity to link
147 environmental and health data on a local, state, and national level, thereby better equipping the public
148 health community to identify problems and effective solutions to reduce the burden of environment-
149 related health effects in the U.S. (CDC, 2009).

150

151

Exposure

153 For humans, the amount of a chemical, physical, or biological contaminant at the outer boundary of the
154 body available for exchange or intake via inhalation, ingestion, or skin or eye contact (EPA, 2008).

155

Exposure assessment

157 The process of finding out how people come into contact with a hazardous substance, how often and for
158 how long they are in contact with the substance, and how much of the substance they are in contact with
159 (ATSDR, 2009).

160

Exposure level

162 The amount of a chemical at the absorptive surfaces of an organism (EPA, 2006).

163

Exposure pathway

165 The route a substance takes from its source (where it began) to its end point (where it ends), and how
166 people can come into contact with (or get exposed to) it. An exposure pathway has five parts: a source of
167 contamination (such as an abandoned business); an environmental media and transport mechanism (such
168 as movement through groundwater); a point of exposure (such as a private well); a route of exposure
169 (eating, drinking, breathing, or touching), and a receptor population (people potentially or actually
170 exposed). When all five parts are present, the exposure pathway is termed a completed exposure pathway
171 (ATSDR, 2009).

172

Health outcomes

174 Documented change in health status using disease-specific measures. Data on health outcomes are
175 obtained from actively or passively collected data on clinical events and personal health and illness
176 experiences (e.g. vital records, reported illness, and health surveys).

177

Monitoring

179 Periodic or continuous surveillance or testing to determine the level of compliance with statutory
180 requirements and/or pollutant levels in various media or in humans, plants, and animals (EPA, 2006).

181

182 See also Appendix C. "Acronyms."

183

Caveats and/or Limitations

184

186 Given the wide scope of the Monitoring Work Group Charge, it was not possible to address all areas in
187 depth. By splitting into subgroups, the work group's aim was to be as thorough as possible while still
188 addressing the range of topics falling within the work group's purview. The work group also attempted to
189 bring forward the range of ideas presented during subgroup discussions. This draft report represents a
190 synthesis of the key information and overarching recommendations discussed by the work group, and is
191 not necessarily a consensus document on at this time.

192

193

II. Current Status of Issues under Consideration

194

196 The current status of the nation's knowledge of chemical use, environmental concentrations, levels within
197 humans and other species, and consequent health effects can best be characterized as partial, uneven and
198 minimally integrated. There are numerous data sources for all categories, which vary in terms of
199 accuracy, comprehensiveness, and usefulness of information. This section characterizes the major
200 elements of the nation's chemical management systems that relate to understanding chemical sources,

201 use, exposures, and health effects in the US population. The strengths and limitations are discussed for
202 each category of monitoring and surveillance information, and barriers and challenges to a better
203 functioning set of systems explored.

204

205

206 **Chemical Use and Release**

207

208 Major Components of Chemical Use and Release Monitoring

209

210 The United States Environmental Protection Agency (EPA) has lead responsibility for tracking the uses of
211 industrial chemicals and pesticides as well as their release into the environment. Major components of the
212 EPA's system include the Toxic Substances Control Act (TSCA) Chemical Substance Inventory, the
213 Pesticide Product Information System (PPIS), the Toxics Release Inventory (TRI), National Emissions
214 Inventory (NEI), and National Pollutants Discharge Elimination System (NPDES).

215

216 *TSCA Chemical Substance Inventory*

217 TSCA § 8(b) requires EPA to manage and publish a current list of chemical substances manufactured or
218 processed in the United States. The substances included in the TSCA Chemical Substance Inventory are
219 any "...organic or inorganic substance of a particular molecular identity, including - (i) any combination
220 of such substances occurring in whole or in part as a result of a chemical reaction or occurring in nature,
221 and (ii) any element or uncombined radical" (Toxic Substances Control Act, 1976).

222

223 EPA's New Chemicals Program requires anyone planning to manufacture or import a new chemical
224 substance for a non-exempt commercial purpose to provide a premanufacture notice (PMN) to EPA at
225 least 90 days before the manufacture or import of the chemical. EPA requires that PMN submissions
226 provide all available data on chemical identity, production volume, byproducts, use, environmental
227 release, disposal practices, and human exposure. EPA also requires that the following information be
228 submitted with the PMN: all existing health and environmental data in the possession of the submitter,
229 parent company, or affiliates, and a description of any existing data known to or reasonably ascertainable
230 by the submitter (EPA, 2010a).

231

232 *Pesticide Product Information System*

233 EPA's Pesticide Product Information System (PPIS) contains information concerning all pesticide
234 products registered in the United States. It includes registrant name and address, chemical ingredients,
235 toxicity category, product names, distributor brand names, site/pest uses, pesticide type, formulation code,
236 and registration status (EPA, 2010b).

237

238 *Toxics Release Inventory*

239 Section 313 of the Emergency Planning and Community Right-to-Know Act of 1986 (EPCRA) requires
240 EPA and states to annually collect data on releases and transfers of certain toxic chemicals from industrial
241 facilities and make the data publicly available in the Toxics Release Inventory (TRI) (EPA, 2010c).

242

243 According to EPA (2010d), companies meeting all of the following criteria are required to report the
244 amount of chemicals released per year and to what medium releases occurred:

245

246

247

248

249

250

251

The general types of data in TRI Basic data format include the following:

- 252 • Facility Name, Address, Latitude & Longitude Coordinates, and Standard Industrial
- 253 Classification (SIC) or NAICS codes;
- 254 • Chemical Identification and Classification Information;
- 255 • On-site Release Quantities;
- 256 • Publicly Owned Treatment Works (POTW) Transfer Quantities;
- 257 • Off-site Transfer Quantities for Release/Disposal and Further Waste Management; and
- 258 • Summary Pollution Prevention quantities (Section 8 of the Form R) (EPA, 2010e).
- 259

260 *National Emissions Inventory*

261 EPA's National Emission Inventory (NEI) database contains information about sources that emit criteria
262 air pollutants and their precursors, and hazardous air pollutants. The database includes estimates of annual
263 air pollutant emissions from point, nonpoint, and mobile sources in the states, the District of Columbia,
264 Puerto Rico, and the Virgin Islands. EPA collects information about sources and releases an updated
265 version of the NEI database every three years (EPA, 2008b).

266

267 *National Pollutant Discharge Elimination System*

268 As authorized by the Clean Water Act, the National Pollutant Discharge Elimination System (NPDES)
269 permit program regulates point sources that discharge pollutants into waters of the United States. The
270 NPDES program is primarily administered by states (EPA, 2009).

271

272 Strengths and Limitations of Chemical Use and Release Monitoring

273

274 Public access to data on chemical use and release is relatively high in the United States compared to other
275 countries. In addition to informing individuals and communities about their potential risks, it has been
276 suggested that the requirement of public disclosure of information on chemical use and toxic substance
277 release has contributed to voluntary actions on the part of industries to limit the production and release of
278 hazardous substances (Karkkainen, 2001; Stephan, 2002). While it is difficult to document decisions
279 made by companies based on TSCA provisions, the TRI database has been cited as a success.²

280

281 Despite these successes, however, there are many recognized limitations to the ways chemical use and
282 release data are collected in the United States. First, there is no single system that tracks all potentially
283 harmful chemical substances; instead, information is split among a number of different systems created
284 by different statutes, i.e., for pesticides, food additives, cosmetics, pharmaceuticals, and industrial
285 chemicals. In fact, only chemicals not covered by any other statute may be covered under the Toxic
286 Substance Control Act.³ This makes understanding cumulative exposures more challenging, as the
287 information on potential chemical exposures is fragmented by the different statutory systems. Second, the
288 data obtained on chemical uses is insufficient to understand potential exposures to the extent necessary to
289 protect the public. For example, the information provided on potential children's exposure under EPA's
290 Inventory Update Rule does not include the potential for children to be exposed in homes through the use
291 of chemicals by their parents; it only asks for chemicals in products intended for use by children
292 themselves to be identified (EPA, 2008c). Third, much of the information requested on chemical use is
293 unavailable to the public and often to the government itself because of the invocation of Confidential
294 Business Information (CBI) censorship or claims of information not being reasonable obtainable. The

² For example, TRI exceeded its goal of a 50% reduction in the release and transfer of 17 targeted chemicals under the "33/50" program, which ran from 1990-1995. See

http://www.epa.gov/tri/archive/othertriprog/33_50other_federal.htm.

³ See <http://www.epa.gov/oppt/newchems/pubs/invntory.htm> for more information on the TSCA Chemical Substance Inventory.

295 EPA has recently taken measures to reduce the use of CBI claims by requiring companies to better justify
296 the need for such privileges.⁴

297

298 **Environmental Monitoring**

299

300 Major Components of Environmental Monitoring

301

302 Many federal, state, and other organizations in the U.S. collect environmental data for a wide variety of
303 purposes. Some of these data collection efforts are more directly targeted at understanding human
304 exposures, while others are focused on understanding effects on ecosystems and/or non-human species. In
305 addition, some environmental data collection efforts are massive and comprehensive, while others are
306 limited in their scope. This leads to a patchwork of coverage of the different environmental media
307 relevant to public health. Ambient air monitoring, for example, is conducted across the U.S. to document
308 compliance with the National Ambient Air Quality Standards (NAAQS). Similarly, water monitoring
309 programs are conducted to ensure that drinking water meets currently applicable standards. Monitoring
310 chemicals and agents in food items contributes to ensuring food safety.

311

312 Selected major components of environmental monitoring data at the federal level include:

313

314 *EPA's National Contaminant Occurrence Database*

315 The National Contaminant Occurrence Database (NCOD) is a national database of contaminants, both
316 regulated and unregulated, in public water systems. Unregulated contaminant occurrence data; Six-Year
317 Review of National Drinking Water Regulations; and ambient/source water data are all included in
318 NCOD data. Unregulated contaminant occurrence data are for contaminants without health-based
319 standards under the Safe Drinking Water Act (SDWA) at the time of monitoring. They are used to inform
320 the EPA Administrator whether or not to regulate those contaminants. The Six-Year Review is the
321 required review of each National Primary Drinking Water Regulation by EPA and includes SDWA
322 compliance monitoring data for regulated drinking water contaminants from public water supplies. Two
323 ambient water quality data management systems – the Legacy Data Center and STORET – contain raw
324 biological, chemical, and physical data on surface and ground water. All 50 states, territories, and U.S.
325 jurisdictions, as well as portions of Canada and Mexico, are represented in these ambient/source water
326 data systems (EPA, 2010f).

327

328 *EPA's Ambient Air Monitoring Networks*

329 Ambient monitoring data obtained from EPA's monitoring systems are used to develop and determine
330 compliance with the National Ambient Air Quality Standards (NAAQS), characterize air quality trends,
331 develop emission control strategies, and support research on health effects of air pollution. Since the
332 1970s, ambient air quality data have come from State and Local Air Monitoring Stations (SLAMS).
333 SLAMS monitor all criteria pollutants, namely, sulfur dioxide [SO₂], nitrogen dioxide [NO₂], carbon
334 monoxide [CO], ozone [O₃], lead [Pb], and particulate matter ([PM_{2.5}] and [PM₁₀]). These stations use
335 Federal Reference Methods (FRMs) or Federal Equivalent Methods (FEMs) for direct comparison to the
336 NAAQS, which leads to areas being designated in attainment or non-attainment of a standard. At the end
337 of 2007, there were approximately 947 FRM/FEM filter-based monitors and 591 continuous measurement
338 monitors making PM_{2.5} mass measurements. Further, there were approximately 943 PM₁₀ monitors, 1216
339 O₃ analyzers, 389 CO analyzers, 519 SO₂ analyzers, 422 NO₂ analyzers, and 172 Pb monitors (EPA,

⁴ EPA announced in May 2010 that it will take on “a general practice of reviewing confidentiality claims for chemical identities in health and safety studies, and in data from health and safety studies, submitted under TSCA.” See <http://edocket.access.gpo.gov/2010/pdf/2010-12646.pdf>. In addition, in August 2010, EPA issued a proposed rule to modify the TSCA IUR rule. See the docket at <http://www.regulations.gov/search/Regs/home.html#docketDetail?R=EPA-HQ-OPPT-2009-0187>.

340 2008d). Despite these numbers, significant temporal and spatial gaps remain in criteria pollutant
341 monitoring across the US. For example, monitors are generally placed away from important sources of
342 pollution, such as major roadways, and so may not capture actual exposures of significant populations.
343

344 In addition to SLAMS networks, the Photochemical Assessment Monitoring Station (PAMS) network
345 was developed and implemented in the mid-1990s to measure ozone precursors such as volatile organic
346 compounds, nitrogen oxides [NO_x], and reactive nitrogen species. The PAMS network consists of 78 sites
347 in areas that are classified as serious ozone non-attainment areas. As part of the PM_{2.5} NAAQS review
348 completed in 1997, EPA established a PM_{2.5} Chemical Speciation Network (CSN) for routine speciation
349 monitoring of particulate matter. There are approximately 210 CSN sites collecting data on PM_{2.5} mass,
350 trace elements, major ions (sulfates, nitrates, and ammonium), and organic and elemental carbon
351 fractions. Interagency Monitoring of Protected Visual Environments (IMPROVE) network was
352 established in 1985 to monitor PM_{2.5} levels in national parks and wilderness areas (EPA, 2008d). The
353 IMPROVE network presently comprises of 110 regionally representative monitoring sites, and some sites
354 that operate collaboratively with the CSN. For air toxics (also known as hazardous air pollutants [HAPs]),
355 EPA's monitoring efforts include National Air Toxics Trends Stations (NATTS), funding existing state
356 and local monitoring of air toxics, and community-scale projects to assess conditions at the local level.
357 EPA's recent strategy is to focus on multi-pollutant monitoring and the Agency has recently implemented
358 the National Core (NCore) Network. NCore integrates several advanced measurement systems for
359 particles, pollutant gases and meteorology. NCore stations will be fully operational by Jan 2011 with 82
360 monitors covering urban (62 sites) and rural areas (20 sites) (EPA, 2008d).

361
362 *Food and Drug Administration's (FDA) Total Diet Study*

363 The Total Diet Study, also called the market basket study, is an FDA program that studies various
364 contaminants and nutrients in foods consumed by the U.S. population. The Total Diet Study assesses key
365 members of the following analyte groups: pesticides, industrial chemicals, elements, radionuclides, and
366 moisture (FDA, 2009).

367
368 *US Geological Survey (USGS) Water Quality Monitoring*

369 The USGS provides information on the nation's water quantity and quality from programs that comprise
370 the largest ambient water monitoring activity in the nation, information on the effects and exposure of
371 environmental contaminants to the nation's living resources, particularly those under the stewardship of
372 the Department of the Interior, and information on the environmental health implications of development
373 of energy and mineral resources. The information provides a scientific basis for decisions by resource
374 managers, regulators, industry and the public.

375
376 The National Water Quality Assessment (NAWQA) Program assesses pesticides, volatile organic
377 compounds, nutrients and trace elements in the nation's ground water and surface water. Information on
378 the quality of source and finished drinking water and the water quality of domestic wells is collected as
379 well. The Toxic Substances Hydrology Program develops methods to assess new and under-studied
380 environmental contaminants and augments NAWQA Program assessments.⁵

381
382 Strengths and Limitations of Environmental Monitoring

383
384 Environmental monitoring provides data for use by resource managers, regulators, industry and the
385 public. These data are used for evaluating potential regulations related to chemical registration, use, and
386 release to the environment, and development of new environmental quality standards. Still, despite the
387 large number of programs and the wealth of data collected, there is a lack of systematic data collection

⁵ The USGS water information is stored in, and accessible from, the National Water Information System (NWIS), which includes over 4.4 million historical water quality analyses. See <http://water.usgs.gov>.

388 that can be readily used to characterize and fully assess human exposure to chemicals or other agents at
389 the community or national level. Thus, a major limitation of the United States' current environmental
390 monitoring system is that both monitoring of environmental media and the collection of necessary
391 ancillary information are incomplete, fragmented and often not collected frequently enough for useful
392 interpretation.

393
394 Enhanced cross-agency integration of existing efforts and collaboration on future activities would
395 increase information value far above that of studies conducted in isolation. For example, linking existing
396 time activity programs such as the American Time Use Survey (ATUS), which is conducted by the
397 Bureau of Labor Statistics in the Department of Labor, to existing environmental monitoring programs
398 conducted by the EPA, USGS and other agencies, could provide far more useful information than either
399 activity alone. Cooperation from the Bureau of Labor Statistics would be needed to expand the
400 information collected in the ATUS to make it more relevant for environmental exposures. Together, they
401 could provide a basis for estimating human exposure based upon a better knowledge of contact with the
402 monitored media and, if appropriate information is collected, identification of potential sources of
403 exposure. The integrated information provides a greater ability to reduce exposures, if warranted, by
404 understanding the key factors contributing to exposure. The types of ancillary information needed to place
405 monitoring data into an exposure context include information on how and where people spend their time
406 (time-activity studies), occupation, product use patterns, food consumption patterns, and indoor
407 environment characteristics (i.e., room size, ventilation). The relative importance of each of these types of
408 information will vary based upon the substances being monitored, and this should be considered in study
409 design.⁶

410
411 Along with the lack of interconnectedness among monitoring programs for various environmental media,
412 there are unique challenges associated with monitoring efforts for specific media. A major limitation of
413 water monitoring programs, for example, is the difficulty of measuring numerous new chemicals that are
414 used each year while keeping track of traditional environmental contaminants. While bioassays that assess
415 the overall biological activity of a water sample rather than a concentration of a specific chemical show
416 potential as screening tools, chemical-specific identification will inevitably be required to identify, and
417 track the performance of, remedial actions.

418
419 In addition, there is a particular lack of data on exposure in the indoor environments that constitute the
420 location of occupancy for over 90% of the time for many individuals (EPA, 2010g). For example, the
421 most current data on human exposures in the workplace are 30 years old, resulting in a severely
422 compromised understanding of risks related to occupational exposures. The National Institute for
423 Occupational Safety and Health (NIOSH) should address this weakness by conducting nationally
424 representative surveys of workplaces across all industries. While a limited number of programs have
425 collected environmental data to obtain distributions of chemicals in multimedia samples in indoor
426 environments (e.g., the Department of Housing and Urban Development (HUD) has conducted
427 monitoring in homes and other environments, often in collaboration with other agencies, such as EPA and
428 the Consumer Product Safety Commission [CPSC]⁷), there are no systematic indoor surveillance
429 programs.

430
431

⁶ Further guidance on these considerations can be found in EPA's Guidelines for Exposure Assessment and in EPA's Exposure Factors Handbook and Child Specific Exposure Factors Handbook. See <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=20563>. A new version of this important handbook is anticipated to be released in the coming year.

⁷ Examples include a child care center study in 2001 and a series of healthy homes studies, most recently in 2005. See <http://www.hud.gov/offices/lead/researchers.cfm>.

432 Biomonitoring

433

434 Major Components of Biomonitoring

435

436 Human exposure to naturally-occurring and manufactured chemicals has long been a concern to the
437 general public, health professionals and policymakers. Potentially harmful chemicals may be present in
438 food, water, soil, air and consumer products. Measuring levels of chemicals in the environment helps
439 scientists and policy makers understand the magnitude and distribution of potential problems, but these
440 measurements are not always predictive of how much of a chemical has been absorbed or who may be
441 most affected by this exposure. Biomonitoring provides a precise measure of the concentration of a
442 chemical in a specific body fluid or in exhaled air. Thus, biomonitoring measurements reflect an
443 individual's exposures to a specific chemical or set of related chemicals from all sources, and can help
444 identify groups of people who may be more or less exposed to a given chemical.

445

446 *CDC's National Biomonitoring Program*

447 For at least three decades, scientists at CDC's Environmental Health Laboratory have been undertaking
448 efforts to determine which environmental chemicals are of high priority and measuring the levels of these
449 chemicals in a representative sample of the civilian, noninstitutionalized US population. The *Fourth*
450 *National Report on Human Exposure to Environmental Chemicals* includes exposure data for 212
451 chemicals and chemical metabolites in a sample of about 2400 participants that represents the U.S.
452 civilian, noninstitutionalized population (CDC, 2010a).

453

454 *States and Biomonitoring*

455 State health departments use biomonitoring to support environmental exposure investigations and help
456 address concerns regarding environmental exposures that might be unique to their state. For example,
457 uranium occurs naturally in ground water throughout the Rocky Mountains as well as in South Carolina,
458 Connecticut, and other eastern states. Because CDC cannot address all of the environmental exposures in
459 each state, the agency provides competitive funding to help states build their own biomonitoring
460 capability.⁸

461

462 *Other Large-Scale Biomonitoring Efforts*

463 Other countries and consortia of national programs have carried out biomonitoring surveys in the past,
464 though these have usually been restricted to one class of chemicals at a time (e.g., metals). Two large-
465 scale national biomonitoring efforts are ongoing: the *German Environmental Surveys I-IV* and the recent
466 *2010 Report on Human Biomonitoring of Environmental Chemicals* from Statistics Canada and Health
467 Canada. Several other nations are planning to build biomonitoring programs.

468

469 *Biomonitoring and Research*

470 In addition, with the spread of newer technologies, biomonitoring methods are applied to research studies
471 that often include smaller, localized populations. These biomonitoring data are useful not only within the
472 context of the research study that sponsors the data collection but also for comparison purposes with
473 national data. CDC performs advanced biomonitoring measurements for about 50 new research studies
474 each year.

475

⁸ See http://www.cdc.gov/biomonitoring/state_grants.html for information on CDC funding of state-based biomonitoring programs. See <http://www.aphl.org/aphlprograms/eh/chemicalpeople/Documents/BiomonitoringReport2009.pdf> for a detailed discussion of biomonitoring in some of the states.

476 *Impact and Applications*

477 Biomonitoring data have increased awareness of the incidence and magnitude of chemical exposures for
478 the public, for scientists, and for decision makers. Biomonitoring has played a prominent role in
479 documenting the effectiveness of regulatory interventions, and in some cases has contributed to chemical
480 management actions because of alarming or surprising results. One notable example of the former is lead.
481 Since the late 1970s, the blood lead levels for children aged 1-5 years old have declined over 90%
482 because of the removal of lead from gas and paint (CDC, 2008). Similarly, National Health and Nutrition
483 Examination Survey (NHANES) data have documented reductions in human levels of DDT,
484 organochlorine pesticides, lead, environmental tobacco smoke. Biomonitoring has demonstrated near-
485 ubiquitous exposure to certain phthalates, such as diethylphthalate (DEP), diethylhexylphthalate (DEHP),
486 dibutylphthalate (DBP), and benzylbutylphthalate (BBP), with higher levels in women of childbearing
487 age and young children (Blount et al., 2000; Silva et al., 2004). These findings from biomonitoring, in
488 conjunction with growing concerns about reproductive and developmental toxicity of those same
489 compounds, were part of the justification for the development of EPA's action plan on phthalates⁹ and
490 preceded federal (i.e., Confidential Information Protection and Statistical Efficiency Act §108) and state
491 (i.e., California Assembly Bill 1108) legislation banning or restricting the use of these same compounds
492 in products for children. Similarly, demonstration of increasing levels of polybrominated diphenyl ethers
493 and widespread exposures to bisphenol A has helped motivate state, federal, and international actions to
494 reduce exposure to these chemicals.

495
496 Biomonitoring is generally more useful for chemicals that persist for a long time in the body, like DDT
497 (dichlorodiphenyltrichloroethane) and lead. However, such sampling cannot as a rule distinguish various
498 historical exposure scenarios (i.e. – one cannot tell whether the lead exposure was a week ago, a year ago,
499 or a decade ago based on a blood level alone- ancillary information is necessary). One particularly useful
500 application of biomonitoring is in the workplace, where exposure data are more readily obtained. For
501 example, under the occupational health standard for inorganic lead, a program of biological monitoring
502 and medical surveillance is to be made available to all employees exposed to lead above the action level
503 of 30 ug/m(3) TWA for more than 30 days each year. This program consists of periodic blood sampling
504 and medical evaluation to be performed on a schedule which is defined by previous laboratory results,
505 worker complaints or concerns, and the clinical assessment of the examining physician. It allows for
506 workers to be removed from exposure when their blood levels exceed a given threshold.¹⁰

507
508 Biomonitoring may also be useful for chemicals with shorter half-lives when exposure to those chemicals
509 is sufficiently widespread and frequent (or continuous) that a random sample is likely to find that
510 chemical or its metabolites at concentrations reflective of overall population or individual levels. It may
511 also be helpful for short-lived chemicals if sampling can be appropriately coordinated with exposure (e.g.,
512 end of shift workplace monitoring). Biomonitoring may be particularly useful when there are multiple
513 pathways of exposure (air, food, water, etc.), as it allows a picture of overall intake to be obtained. This
514 has been the case for some of the phthalate chemicals mentioned above.

515
516 Strengths and Limitations of Biomonitoring

517
518 Biomonitoring provides a direct measurement of the internalized dose of a chemical and may, for many
519 chemicals, reduce the uncertainty associated with other methods of assessing exposure, such as activity
520 questionnaires and modeled estimates based on measurements of environmental media like ambient air
521 and drinking water. A strength of biomonitoring is that it measures the dose delivered from all routes of
522 exposure (i.e., air, water, food, soil). Often people are exposed through multiple routes. For example,

⁹ See www.epa.gov/oppt/existingchemicals/.../phthalates_ap_2009_1230_final.pdf.

¹⁰ See http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=10033 for more information about medical surveillance guidelines for occupational exposure to inorganic lead.

523 children who live in older homes may eat paint containing lead that is peeling off the walls; they may
524 breathe or eat lead from paint that has been ground or eroded into fine particles and mingled with the dust
525 in the house; and they may drink lead in their water if their plumbing contains lead. All of these exposures
526 would be captured in a child's blood lead level. On the other hand, to estimate this cumulative exposure
527 using environmental monitoring, one would need to take samples of the air, paint, dust and water, run
528 separate tests on each sample, and then enter those results into a mathematical model to estimate the
529 internal dose. Biomonitoring also provides a way to assess combined environmental and occupational
530 exposures.

531
532 In epidemiologic studies, biomonitoring can assist with case confirmation and also can be used to validate
533 the sensitivity or specificity of less-invasive, less-costly indirect surveillance methods (Acquavella,
534 Alexander, Mandel, & Gustin, 2006). Since biomonitored levels reflect the concentration of chemicals in
535 specific compartments of the body, these levels are likely to have a stronger statistical association with
536 internal effects, such as genetic damage or cell death (in related body compartments especially), and often
537 with health outcome measures such as decreased IQ or disease incidence.

538
539 In the risk assessment process, biomonitoring data can be used to validate or compare dose-based
540 regulatory values by means of forward and reverse dosimetry. For instance, population data on levels of
541 perchlorate in urine can be used to calculate an intake dose of the chemical and compare this value to the
542 EPA reference dose (RfD). In addition, biomonitoring can help scientists to identify which levels of
543 chemicals actually occur in people and help to target research studies at those levels. Lastly, future
544 advantages will be yielded when animal dosing studies of effects are designed to include blood and urine
545 levels that are associated with those effects; then these animal levels can be more directly compared with
546 those in humans, supplementing the less certain dose-to-dose comparisons with level-to-level
547 comparisons.

548
549 Still, there are a number of technical and practical limitations to biomonitoring. Not all chemicals can be
550 biomonitored; laboratory methods for many chemicals have not yet been developed or else they may only
551 be able to detect chemicals at higher concentrations than are relevant for human exposures; in addition,
552 some methods are not feasible due to cost, or capacity limitations.

553
554 A major impediment to biomonitoring, especially of blood and particularly in children, is the need for an
555 invasive procedure. The use of urinary, salivary, hair, breath, or other sampling that can be performed in a
556 non-invasive manner is generally preferred, and efforts are needed to improve the availability and
557 reliability of non-invasive biomonitoring methods.

558
559 Also, for most biomonitored chemicals, the interpretation of test results is a major challenge. Because of
560 inadequate scientific understanding of the extent to which measured concentrations of chemicals in blood
561 and urine are associated with, let alone predictive of health effects, biomonitoring at present can often
562 only provide insight into exposures without giving individuals and policy makers useful information on
563 the likelihood of specific health effects. Well designed research studies that take into account important
564 co-factors such as physiologic state, pharmacokinetic variation, diet, nutrition, and underlying health-
565 related disorders are needed to help better understand the connections between biomonitored chemical
566 concentrations and health effects.

567
568 Biomonitored levels of chemicals in the absence of other exposure-related information usually cannot
569 indicate where (location) a person was exposed, the duration or frequency of exposure, the route of
570 exposure (oral, inhaled, dermal), or the source of the exposure. Other information should be used together
571 with the biomonitoring data to make risk assessment and policy decisions. For non-persistent chemicals
572 that may produce effects due to prolonged exposure, many biomonitored levels during the exposure

573 period would be required to estimate long term risk most accurately. For persistent chemicals in the body,
574 single measurements can be a good indicator of body burden.

575
576 Currently, technology, history, and concerns for suspected toxic chemicals are driving the selection of
577 chemicals that are biomonitoring. It is likely that additional, unmeasured chemicals have entered the
578 environment and human's bodies. Rational future selection of chemicals to biomonitor will be limited by
579 the level of understanding of toxicity of the broader range of chemicals and by the amount of information
580 available on the release of chemicals into the environment and uses of chemicals.

581
582 Standardization of biomonitoring practices and methods is often lacking, compromising the reliability and
583 comparability of data from different studies. For example, in individual biomonitoring testing,
584 standardization of collection timing with respect to timing, duration and frequency of the exposure is
585 extremely important to avoid biasing the results and subsequent assessments, particularly in smaller
586 samples in which such bias may be more prominent. Different instruments or analytical methods often
587 make it difficult to generate accurate and reproducible results across different studies. CDC and many
588 state public health laboratories are working together to standardize methods, calibrator materials, and
589 quality assurance procedures to assure better comparability of biomonitoring data.

590
591

592 **Health Outcomes**

593

594 Major Components of Health Outcomes Monitoring

595

596 Ongoing monitoring of health status, health outcomes, and health conditions associated with chemical
597 exposures in the United States occurs at the federal, state and local levels. At all levels, technological
598 advancements have improved the timeliness of data and its accessibility, increased the ability to use
599 geographic information, and led to more timely release of health reports and micro-data. Partnerships
600 between federal, state and local public health officials have built on these advances to develop more
601 coordinated systems for monitoring data from diverse sources for specific locations (e.g., CDC's
602 Environmental Health Tracking program¹¹ and the HHS Community Health Data Initiative¹²).

603

604 Systems for monitoring health outcomes in the context of chemical exposures can be broadly divided into
605 two basic categories: (a) state and local systems for identifying and investigating disease clusters and
606 outbreaks in order to identify potential environmental causes; and (b) ongoing state and national health
607 data collection systems, which collect data on general health indicators that may or may not be related in
608 part to chemical exposures. There are many limitations to the use and interpretation of existing health data
609 sets for environmental health assessment, as most data sets are collected for other purposes. Relevant
610 examples of health outcomes data systems are described below.

611

612 *Reportable Conditions and Other Ongoing State Reporting Systems*

613 Health outcome monitoring at the state and local levels through case reporting is based on the legal
614 mandates states have for requiring reporting of individuals with selected health conditions. Case-based
615 surveillance is well established for communicable diseases and cancer. Currently only a limited number
616 of health conditions related to chemical exposures are reportable in more than one state. They include
617 poisonings and laboratory test results related to several heavy metals (lead, mercury, cadmium, arsenic),
618 pesticide poisoning, carbon monoxide poisoning, pneumoconiosis, chemical pneumonitis, and other

¹¹ See <http://www.cdc.gov/nceh/tracking> for more information on CDC's Environmental Public Health Tracking program.

¹² See http://www.cdc.gov/nchs/data_access/chdi.htm for more information on the Community Health Data Initiative.

619 chemical poisonings. Only three of these conditions are reportable in 50% or more of the states (lead
620 poisoning/elevated blood lead, pesticides, and silicosis – one of the types of pneumoconiosis). Several
621 other conditions that have been made reportable by states are of interest to environmental public health
622 surveillance because of their possible links to chemical exposures. These include cancer, autism,
623 Parkinson’s disease, asthma, and birth defects; although cancer is reportable in almost all states, the other
624 four conditions are reportable in relatively few.¹³

625
626 Ongoing monitoring using health data systems other than conditions reportable at the state level includes
627 use of vital records, state hospital discharge data systems (available in most states), emergency
628 department data (available in some states), birth defects registries¹⁴ (funded by CDC in nine states), the
629 Behavioral Risk Factor Surveillance Survey (BRFSS) survey, cancer registry data (all states), and others.

630
631 At the national level, many health data systems are in place to monitor the health of the US population. In
632 some cases states provide data to federal agencies in uniform formats, while other systems are
633 administered directly by federal agencies.

634
635 *CDC’s National Vital Statistics System*

636 The National Vital Statistics System collects and disseminates information on the nation’s vital events
637 (e.g., deaths, births, fetal deaths) through partnership with the jurisdictions legally responsible for their
638 registration. These data provide information on a variety of health endpoints, including cause of death and
639 infant birth weight, information that could be associated with chemical exposures. Further, because these
640 data are collected locally, detailed geographic information may be available when directly obtained from
641 a state (CDC, 2010b).

642
643 *Large National Health Surveys*

644 Large national health surveys, including the National Health Interview Survey¹⁵ and the National Health
645 and Nutrition Examination Survey (NHANES)¹⁶ collect a wide variety of information on health and
646 health-related behaviors. These surveys have the advantage of relatively large sample sizes, information
647 for small population subgroups, and consistency over time to monitor health trends. On the other hand,
648 they are not designed to provide local information and are in fact prohibited from doing so to protect
649 participant’s confidentiality and avoid disclosure risks. There are also some local surveys modeled after
650 the national surveys, such as the California Health Interview Survey and the New York City Community
651 HANES.¹⁷ These, however, can be limited in their time frame and sample sizes, and they represent large,
652 rather than local, areas.

653
654 *The Behavioral Risk Factor Surveillance Survey (BRFSS)*

655 The BRFSS is a large, ongoing telephone-based health survey, tracking health conditions and risk
656 behaviors in the United States annually since 1984. This state-level data system collects information on a
657 variety of health conditions and produces estimates for some subsections of states.

658

¹³ The enumeration of states that have made any of these conditions reportable can be found on a searchable website maintained by the Council of State and Territorial Epidemiologists (CSTE). See <http://www.cste.org/dnn/ProgramsandActivities/PublicHealthInformatics/StateReportableConditionsQueryResults/tabid/261/Default.aspx>

¹⁴ See <http://www.cdc.gov/ncbddd/bd/monitoring.htm> for more information on birth defects monitoring.

¹⁵ See <http://www.cdc.gov/nchs/nhis.htm> for more information on the National Health Interview Survey.

¹⁶ See <http://www.cdc.gov/nchs/nhanes.htm> for more information on NHANES.

¹⁷ See <http://www.chis.ucla.edu> for more information on the California Health Interview Survey, and <http://www.nyc.gov/html/doh/html/hanes/hanes.shtml> for more information on the New York City Community HANES.

659 Outcomes and events from administrative records are also used in several ways at the national level.
660 Medical records with information on diagnosis and treatment of disease are sampled via National Health
661 Care Surveys¹⁸ and aggregated via the Healthcare Cost and Utilization Project.¹⁹ Other claims-based data
662 systems such as the Medicare claims data²⁰ could be used to monitor specific health outcomes. Other
663 sources, such as data files maintained by large insurance companies or emergency departments may be
664 available for some purposes. Cancer incidence data are collected nationally through the system of
665 state/regional/local cancer registries. Some of these registries participate in the federally funded
666 Surveillance, Epidemiology and End Results (SEER) program and collect additional in-depth information
667 on cancer incidence, prevalence and survival from specific geographic areas representing 26 percent of
668 the U.S. population (National Institutes of Health, 2010).

669 *Environmental Public Health Tracking*

670 The Environmental Public Health Tracking²¹ (EPHT) network is the only large-scale health surveillance
671 system dedicated to monitoring the health impacts of chemicals. EPHT is a network of 23 states and
672 CDC's National Center for Environmental Health dedicated to developing surveillance data systems
673 linking hazard, exposure, and health outcomes data in a way that is useful to the public, public health
674 professionals, and researchers concerned about the impact of chemicals on human health. In its
675 development over the last eight years, CDC and participating state health departments have had to address
676 numerous complex issues including data access, data standardization, and information technology
677 challenges to making the data publicly available in a uniform format.

679 *National Children's Study*

680 The National Children's Study²² will be collecting a large amount of information, including health
681 outcomes and environmental exposures, for a large, nationally representative sample of children in the
682 United States over many years.

684 *Community Health Data Initiative*

685 Government and non-governmental organizations have partnered to establish the Community Health Data
686 Initiative (CHDI). CHDI is a network of suppliers and demanders of community health data, indicators,
687 and interventions, convened to improve Americans' knowledge of health and health care system
688 performance. The HHS Health Indicators Warehouse, currently under development, will serve as the data
689 hub for the initiative.²³ Although the CHDI is not specifically designed to monitor health outcomes
690 known and possibly related to chemical exposures, the emphasis on local information may enhance the
691 ability to monitor these health outcomes in local communities. Further, the system does not preclude the
692 inclusion of locally defined exposure values, facilitating the examination of possible exposure-outcome
693 trends and relationships.²⁴

695 Strengths and Limitations of Health Outcomes Monitoring

696 Existing data on health outcomes offer several advantages for improved monitoring of the health
697 outcomes associated with chemical exposures. The large, national health surveys and administrative data
698 collections can provide comparable information across the whole U.S., providing benchmarks and
699
700

¹⁸ See <http://www.cdc.gov/nchs/nchs.htm> for more information on National Health Care Surveys.

¹⁹ See <http://www.ahrq.gov/data/hcup> for more information on the Healthcare Cost and Utilization Project.

²⁰ See http://www.cms.gov/PrevntionGenInfo/20_prevserv.asp for more information on Medicare claims data.

²¹ Current EPHT data are available at <http://www.cdc.gov/nceh/tracking>.

²² Learn more about the National Children's Study at <http://www.nationalchildrensstudy.gov>.

²³ See http://www.cdc.gov/nchs/data_access/chdi.htm for more information on the Community Health Data Initiative.

²⁴ See also <http://www.hhs.gov/open/datasets/about.html>.

701 facilitating comparisons across large geographic regions (and even countries). Large surveys and
702 administrative data collections can also provide statistically valid health information for subgroups
703 defined by demographic characteristics, including measures of race, ethnicity, and socio-economic status.
704 Ongoing, systematically maintained, data collections provide information about trends, which can
705 facilitate the identification of new environmental causes of adverse health outcomes. For less common
706 health outcomes or for understanding trends in local areas, notifiable disease reporting efforts offer useful
707 information.

708
709 Despite these strengths, many of the health data systems described above remain limited in their ability to
710 provide useful information on chemically-related health outcomes for a number of reasons. First, health
711 effects associated with chemicals are often non-specific and could be caused not only by a number of
712 different chemicals, but also by other factors. Thus, information on conditions like cancer, asthma, or
713 adverse birth outcomes may be relevant to chemical exposures but requires extensive additional
714 information on exposures and other individual factors in order to shed light on possible chemical
715 causation. Second, there is often a long lag period, or delay, between the time of chemical exposure and
716 the development of obvious adverse health outcomes. This complicates matching specific chemicals to
717 observed health outcomes. Finally, the scientific relationship between adverse health outcomes and
718 specific chemical exposures is poorly understood for the vast majority of chemicals.

719
720 Because chemical exposures often occur on a local scale, local health outcomes data are needed for
721 detection and monitoring of potential health impacts. Health outcome information from national surveys,
722 however, is not collected in all areas. Moreover, local health outcome information obtained from surveys
723 and other national data sets may not be available at the local level in order to protect individual privacy.
724 Furthermore, health outcome information for local areas generally is limited by small numbers of events
725 which make it harder to achieve statistical significance and support definitive scientific inferences.

726
727 Smaller systems that rely on case reporting are also limited by the many causes of under-reporting, which
728 include access to care, physician recognition of chemical causes of disease, and other barriers to physician
729 reporting of cases.

730
731

732 **III. Vision of a Successful System**

733
734 The nation should have a comprehensive collection of information covering all important chemicals for
735 all relevant populations, including data on chemical source (inclusive of imports), chemical uses,
736 environmental and biological concentrations, and toxicity. These data should be collected in a manner that
737 facilitates analysis, data integration, interpretation and most importantly, protective actions. Such data
738 would provide communities the ability to understand patterns of local chemical production and use as
739 well as chemical exposure and risk. This data could be integrated across media and across agencies to
740 provide a comprehensive understanding of chemical exposures and potential harms and therefore provide
741 a basis for decision making. An integrated data collection system, combined with improved understanding
742 of the toxic effects of chemicals and the doses at which they can cause harm, will facilitate decision
743 making and help address the difficulties attributing cause-and-effect that arise from the incomplete
744 information collected under the current system.

745
746 Biomonitoring programs will be bolstered by greater scientific understanding of associations between
747 chemical concentrations in blood, urine and other body compartments and health outcomes, as well as by
748 greater understanding of the distribution and time course of chemicals in the body. This knowledge will
749 support the development of non-invasive and highly sensitive new assays that will facilitate more
750 widespread sampling and sampling of vulnerable populations like young children. Interpretation of

751 biomonitoring results will be aided by improved understanding of chemical uses and more robust toxicity
752 data.

753

754 In addition to chemical-specific information, health outcomes data should be collected in a way that
755 facilitates its applications in protecting the public from harmful chemical exposures. Health outcomes
756 data should be collected in a way that smoothly integrates on a time and spatial basis with chemical
757 source, use, and exposure data. Trends in time and space in relevant health outcomes should be
758 systematically analyzed and efforts made to identify potential “hotspots” or early increases in adverse
759 health outcomes, recognizing that simple trend data are not sufficient to show cause-and-effect
760 relationships. Guidance and “benchmarking” of community-level health data can help state and local
761 health officials identify and address community concerns about adverse health experiences.

762

763 Prioritization will be essential as no such data set will ever be complete, and even a reasonably sufficient
764 data collection cannot be achieved rapidly given available resources and technical barriers. Prioritization
765 should be based on rational criteria (e.g., population vulnerability, chemical production volume, use
766 patterns, mobility, biomonitoring data, toxicity, etc.) and should be set by a committee having
767 representation from multiple agencies as well as other stakeholders and experts based upon aggregate
768 exposures across multiple relevant media. It will be important to recognize that a unitary, ordinal
769 prioritization will probably fail to meet important goals. Thus, prioritization must recognize a range of
770 needs to be met for a variety of reasons, and should take into consideration both national and local needs,
771 address both mortality and life quality issues, and should address agency specific projects and priorities in
772 addition to broader goals.

773

774 This dataset should achieve a robust baseline for sources, uses and environmental exposure in the indoor
775 and outdoor environment and in the workplace in order to support analysis of health outcomes. Regular,
776 representative, and systematic surveillance systems will allow us to understand what current “normal”
777 exposure is and to recognize variation from normal exposures, to identify meaningful exposure inequities,
778 and to document changes over time due to changes in use patterns, intentional interventions (i.e. allow
779 assessment of success or failure), or local or global environmental changes such as global climate change.

780

781 While establishing a robust baseline is critical, the ideal system will also routinely prioritize high-risk
782 communities, populations, and/or chemicals for further study. This could involve additional
783 environmental sampling or small-scale, more intensive biomonitoring studies. Communities shown to be
784 disproportionately exposed to toxic chemicals due to their proximity to intensive industrial production
785 areas or other sources of environmental releases, communities previously found to have elevated levels in
786 prior biomonitoring surveys, and other communities or residences identified as having unusually high
787 concentrations of potentially toxic chemicals can be targeted. Similarly, populations with critical
788 vulnerability, such as fetuses and infants, should be targeted for special investigations. Such studies will
789 provide greater understanding of variations in exposure and risk, as well as providing a means to respond
790 to community needs and identify populations or communities that require additional actions to protect
791 their health.

792

793 The dataset should balance the need for representative data with the need to obtain localized and/or
794 individual-level data. This will allow analysis of local exposure patterns and address specific community
795 concerns yet still facilitate individual-level epidemiological studies and thus avoid the limitations intrinsic
796 to ecological study designs. Exposure data collection should ideally be coordinated with health outcome
797 and/or biomonitoring data on the same individual.

798

799 As with prioritization, an inter-agency team that includes subject experts and state and local partners
800 should establish guidance to ensure compatibility and comparability of data. Technical limitations,
801 differences among media, and other factors may make complete compatibility impossible in some

802 instances, but the need to better understand aggregate exposures across multiple media and exposure
803 pathways would argue strongly for coordination of methods whenever feasible. Environmental and
804 biomonitoring programs in particular should be coordinated to ensure that priority chemicals are being
805 monitored in both programs and that the data are being interpreted jointly to identify and confirm linkages
806 and trends among environmental levels, exposures, and ultimately health outcomes.

807
808 Information should be made publicly available in a useful manner. Transparency is important, and thus
809 the availability of raw data will be important in most circumstances. However, raw data are not
810 necessarily useful information, and so agencies must provide appropriate interpretation of the available
811 data within the limits of available knowledge. The data/information should be provided via an integrated
812 data source. While this could be a single, large database, differential database needs and historical
813 circumstances will probably make a single database difficult to achieve and maintain. Thus, it is more
814 likely that a public-friendly “front-end” web-based resource to coordinate access to key underlying data
815 will be needed to support access needs. There should also be an increased commitment to partnering with
816 academic institutions and community-based groups, to ensure that government-based chemical risk
817 management programs will be well integrated into broader public discussions and decision-making about
818 human and ecosystem health.

819
820 Obtaining optimal data utility will require access to information that may be personally confidential
821 (medical information protected under HIPAA for example) or confidential business information. Data
822 may also carry risks to individuals and communities, including individuals on whom data may not have
823 been directly collected (i.e., localized pollution or localized health issues, even if not causally linked with
824 reasonable certainty, may devalue property or raise significant anxiety, etc.). Thus, the development of a
825 comprehensive national monitoring program must be accompanied by a discussion regarding bioethical
826 issues, and successful deployment of the program may require modifications of existing regulations
827 and/or the establishment of practices such as informed consent. Ultimately, success will likely require a
828 delicate balance between the public good and individual concerns, as is generally the case in public
829 health.

830

831

832 **IV. Action Recommendations**

833

834 **1. Improve reporting of chemical source, use, and discharge information.**

835

836 **(a) Increase the frequency of manufacturing volume reporting required under the Toxic 837 Substances Control Act Inventory Update Rule and require more extensive information on 838 downstream uses.**

839

840 Currently, the Toxic Substances Control Act (TSCA) inventory is updated once every five years. While
841 the amount of use and potential exposure information was expanded in 2006, there are still significant
842 limitations to this information: first, it only reflects one year out of the five year cycle of reporting, so
843 significant fluctuations in production volumes from year to year are missed; second, it only requires
844 information on production volumes, uses, and potential exposures to children be submitted if such
845 information is “readily obtainable” – with no penalty for failing to submit such information if the
846 company claims it is not readily obtainable. The EU REACH program requires that manufacturers of
847 chemicals provide downstream users with information on chemical hazards for specific exposure
848 scenarios; downstream users whose uses are not covered by those exposure scenarios must either notify
849 the upstream supplier of their use or provide their own analysis of potential risks to their customers.²⁵ In

²⁵ The European Chemicals Agency (ECHA) Guidance Document for Downstream Users is available at
http://guidance.echa.europa.eu/docs/guidance_document/du_en.htm?time=1282626622

850 general, REACH is designed to increase communication on hazards and uses both up and down the
851 supply chain.

852
853 The work group therefore recommends that EPA improve the usefulness of TSCA's Inventory Update
854 Rule (IUR). This could be accomplished by increasing the frequency of reporting from every five to every
855 1 or 2 years; requiring greater substantiation of claims of "not readily obtainable" information; and
856 providing clear guidance as to those circumstances under which EPA would accept a claim of "not readily
857 obtainable."²⁶

858
859 **(b) Address Toxics Release Inventory shortcomings; provide more information on short-term**
860 **releases.**

861
862 Instead of relying on nominations for additions to the Toxics Release Inventory (TRI) list, EPA should
863 establish a process of regular scientific review and revision of the TRI. Potential sources for candidate
864 chemicals and industries include scientific peer-reviewed literature, weight-of-evidence evaluations such
865 as the International Agency for Research on Cancer (IARC) and National Toxicology Program (NTP)
866 lists of carcinogens, and state or international identification of high risk chemicals for policy measures.
867 TRI reporting should be tied to information on hazards, uses, and exposures that would result from
868 improved manufacture and use information.

869
870
871 **2. Make environmental monitoring more comprehensive and suitable for assessing total human**
872 **chemical exposure.**

873
874 Federal agencies such as the U.S. Department of Housing and Urban Development (HUD), U.S.
875 Environmental Protection Agency (EPA), the Centers for Disease Control and Prevention's (CDC)
876 National Institute for Occupational Safety and Health (NIOSH), the U.S. Consumer Product Safety
877 Commission (CPSC), U.S. Department of Energy (DOE), and the National Institutes of Health (NIH), and
878 state environmental departments should develop a cross-agency systematic approach to the design and
879 implementation of routine monitoring surveys and expansion of the data collected. The surveys should
880 address: (1) all major microenvironments that people occupy, including residences, child care centers and
881 schools, public access buildings, and workplaces (including offices); (2) the broad spectrum of persistent
882 and non-persistent chemicals in current use in materials and consumer products (e.g., flame retardants,
883 pesticides); and (3) the multiple media to which people are exposed, including diet.

884
885 Monitoring surveys should collect data of sufficient temporal resolution (e.g., in some cases conduct real-
886 time monitoring versus integrated samples) to address acute and chronic exposures to chemicals and to
887 address temporal variability of chemical concentrations in the environment. To make environmental
888 monitoring more comprehensive and suitable for assessing and predicting human exposures, new,
889 innovative, low cost, and low burden monitoring methods need to be developed. In addition to collecting
890 data on chemical concentrations in environmental media, ancillary information (e.g., activity, product
891 use) should be collected in order to make the monitoring data more useful for characterizing people's

²⁶ EPA proposed an IUR Modifications Rule on August 13, 2010. This rule calls for increased frequency of reporting from every five years to every four years; required reporting of production volumes meeting or exceeding the threshold for a chemical substance in any calendar year since the last principal reporting year; required reporting of additional manufacturing and use data; and upfront substantiation of CBI claims, among other changes. See http://www.epa.gov/iur/pubs/Fact%20Sheet_IUR%20ModificationNPRM_08-05-10.pdf for EPA's fact sheet on this proposed rule and <http://www.regulations.gov/search/Regs/home.html#documentDetail?R=0900006480b2ff32> for the docket. The work group may update its IUR-related recommendation prior to submitting the final version of this report to reflect current regulations.

892 exposure to chemicals for different lifestages (children, adults, elderly, and susceptible or vulnerable
893 groups). Surveys need to be conducted on a routine and regularly scheduled basis (every 5 to 10 years) to
894 track trends and identify potential exposure issues.

895
896 The work group recommends that the appropriate agencies and departments enhance cross-organization
897 integration of existing monitoring surveys and expand monitoring surveys. In order to develop a cross-
898 agency systematic and coordinated approach to the design and implementation of routine monitoring
899 surveys, the work group recommends that the appropriate agencies identify an existing inter-agency work
900 group or form a new work group to coordinate monitoring surveys across agencies.

901
902 The measure of success will be demonstration within three years of increased collaboration and
903 coordination across agencies in the planning and conduct of surveys of environmental quality and human
904 exposures.

905 906 **3. Expand biomonitoring capacity**

907
908 The Centers for Disease Control and Prevention's (CDC) *National Report on Human Exposure to*
909 *Environmental Chemicals* provides estimates of chemical exposures for the civilian, noninstitutionalized
910 U.S. population. Its current design was never intended to allow state or local agencies to calculate
911 exposure estimates for their jurisdiction. For example, CDC cannot extract a subset of data and examine
912 levels of blood lead that represent a state population. In order to produce such data, states need the
913 capability and capacity to conduct biomonitoring assessments statewide or in communities or groups
914 where chemical exposure is a concern.

915
916 In order to fill this gap and address community needs, the U.S. needs a state-based, national
917 biomonitoring network of laboratories and public health agencies. The Association of Public Health
918 Laboratories (APHL) has a five-year plan²⁷ to develop a laboratory network and is working with its
919 membership as well as that of the Council of State and Territorial Epidemiologists (CSTE) and
920 Association of State and Territorial Health Officials (ASTHO) to create guidelines for any state or local
921 jurisdiction who chooses to participate in what will be called the National Biomonitoring System.

922
923 Recognizing limited resources, this System should not aim to build capacity in every locality to measure
924 every chemical exposure; however, the network should help localities connect with each other to leverage
925 existing capacity. For an example of such an effort, see the biomonitoring database being developed by
926 APHL to link laboratories with epidemiologists with policymakers and academics to encourage
927 collaboration.

928
929 The ultimate goal would be to at least have the capacity to measure each chemical of concern somewhere
930 in the nation. Because methods only exist for a few hundred of the more than 3,000 chemicals used in
931 high volume in the U.S.,²⁸ we need to develop new laboratory methods and build capacity to measure
932 them locally. It is important to note that in jurisdictions where authorities anticipate an ongoing need to
933 biomonitor a population (for example in jurisdictions doing surveillance studies), redundancies in
934 capacity and capability are encouraged. For example, every state should be able to measure blood lead
935 levels in children. Where appropriate non-invasive sample collection technology is available,
936 biomonitoring studies should be expanded to include children of all age groups.

937

²⁷ More information on APHL's National Biomonitoring Plan is available at
<http://www.aphl.org/aphlprograms/eh/Pages/nationalbioplan.aspx>.

²⁸ EPA classifies High Production Volume (HPV) as those chemicals produced or imported in the United States in quantities of 1 million pounds or more per year. See <http://www.epa.gov/chemrtk/pubs/general/basicinfo.htm>.

938 Systemization will allow standardization of biomonitoring study design, sample collection and analysis,
939 data analysis and comparability, as well as interpretation. Concurrently, legal and financial
940 recommendations will be needed to allow different jurisdictional authorities to take advantage of the
941 network.

942
943 One important action that can be taken quickly (within 1-2 years) is to build carefully designed and well
944 managed human sample banks (blood, milk, tissues such as placenta) and environmental sample banks
945 (fish, tree barks, etc.). These banks will be very helpful in (1) establishing chronology of pollution, (2)
946 identifying new pollutants, (3) tracing back to sources, (4) archiving samples for future analysis with
947 better technology than we have today, (5) exploring regional differences, and (6) carrying out longitudinal
948 studies.

949
950

951 **4. Expand Health Outcome Surveillance**

952 953 **(a) Expand national data surveys to over-sample vulnerable populations and high priority** 954 **geographic regions.**

955
956 Expanding national data surveys and other data collections will allow for better capabilities to understand
957 the variability in health outcomes known and possibly related to chemical exposures across the United
958 States; designing these collections to over-sample specific subgroups will enable better identification of
959 vulnerable populations defined by demographic and socioeconomic indicators. Larger annual sample
960 sizes will reduce the need to combine multiple years of data for accurate estimates, providing better
961 information on current status and trends. Consideration of high priority geographic regions or areas could
962 be considered as a domain in sampling design. This would require statistical research to establish
963 feasibility, implications, and cost considerations. The success of this recommendation would be tracked
964 by broadened use of the data for providing timely estimates for geographic and population subgroups.
965

966 **(b) Expand reportable conditions to other conditions with environmental links.**

967
968 State, local and tribal health departments and CDC have established a process for recommending that
969 health conditions be placed under surveillance at the state and/or national level using the Council of State
970 and Territorial Epidemiologists (CSTE). CSTE, an organization of member states and territories
971 representing public health epidemiologists, has the responsibility for defining and recommending which
972 diseases and conditions are reportable within states and which of these diseases and conditions will be
973 voluntarily reported to CDC. Such recommendations are made through the development of "Position
974 Statements," which include how surveillance should be conducted for a specific condition (e.g., case
975 definition, reportable data elements).
976

977 Accordingly, a work group of CSTE environmental epidemiologists and NCEH epidemiologists should
978 review currently reportable conditions of interest to surveillance of chemical exposures to identify gaps,
979 i.e., conditions that are absent from the current list or those that are on the CSTE list but reportable in
980 very few states. Plans should be developed to address interpretation constraints imposed by limitations of
981 available chemical exposure data and understanding of factors affecting chemical exposure. The work
982 group should develop its recommendations for ways to fill the identified gaps, obtain consensus from the
983 larger group of CSTE environmental epidemiologists, and then develop Position Statements for their
984 recommendations.
985

986 Progress in promoting new and more comprehensive reporting of diseases associated with chemical
987 exposures can be tracked through the CSTE website. The Environmental Public Health Tracking (EPHT)

988 network is likely to place the data on these reportable conditions on the CDC EPHT portal and state
989 portals as appropriate, demonstrating use of these data.

990

991 **5. Expand Environmental Public Health Tracking to include all 50 States and 10 Metropolitan**
992 **Statistical Areas.**

993

994 The concepts and tools of Environmental Public Health Tracking (EPHT), and the Congressional
995 appropriation that has funded the development of the integrated state and federal network, represent the
996 highest level of development of environmental public health surveillance to date, but it has been
997 implemented in only about half of the states because of funding limitations. Additional funding from
998 Congress will need to be secured in order to achieve this recommendation. Organizations representing
999 public health, including the Association of State and Territorial Health Officials (ASTHO), Council of
1000 State and Territorial Epidemiologists (CSTE), National Association of County and City Health Officials
1001 (NACCHO), Association of Public Health Laboratories (APHL), American Public Health Association
1002 (APHA), and others should make EPHT a priority for their discussions with appropriators in Congress.

1003

1004 Increased funding for EPHT from Congress that is directed to additional state health departments will
1005 demonstrate success.

1006

1007

1008 **6. Establish mechanisms for the public and state/local/tribal officials to provide input into data**
1009 **collection efforts.**

1010

1011 **(a) Ensure that effective mechanisms exist for the public and state/local/tribal officials to provide**
1012 **input into decisions about *national data collection efforts*.**

1013

1014 All national data collection mechanisms should be open to public comment through a robust process prior
1015 to their initiation and periodically as preliminary or interim data are collected. The process for fully
1016 capturing community input and concerns is critical to the success of data collection mechanisms. Public
1017 input at the beginning and during data collection projects enables the process to be adjusted and highly
1018 adaptive. Proposed data collection mechanisms and any updates to them should be published on
1019 www.regulations.gov, and public input should be posted in a docket available through the site. The notice
1020 should seek public input on specific issues identified by the responsible agency, as well as allow for open-
1021 ended comment. The public should be encouraged to suggest reformulated questions if they do not find
1022 the agency's questions to be sufficient. The public should have no less than a 120-day comment period.

1023

1024 Agency communication with the public should include but extend beyond a notice in the Federal Register.
1025 Agencies should engage in outreach to national, regional, statewide and local organizations and people.
1026 Accommodation should be made to ensure that materials and translators are available for the languages
1027 spoken by affected communities. At the national level, outreach efforts should target national
1028 environmental, health, labor, religious, and other organizations. Outreach efforts by the responsible
1029 agency should be undertaken to solicit public comment through listening sessions or public administrative
1030 hearings held in each federal region affected by the data collection strategy. All public comments
1031 delivered at the hearings should be transcribed and posted in the docket. This process should provide
1032 public notice that is no less than 30 days. After the public input is received, the agency or agencies in
1033 question should again publish its decision(s) in the Federal Register and seek public input to the docket to
1034 enable any final adjustments.

1035

1036 **(b) Ensure that effective mechanisms exist for the public and state/local/tribal officials to provide**
1037 **input into *local community study design* (e.g., Community-based Participatory Action Research**
1038 **methods).**

1039
1040 Similar to the methodology for public input on national data collection efforts, a local community study
1041 design should seek to involve the members of the community being evaluated. This, too, should be a
1042 process that seeks to ensure broad input from the public with ample opportunity to participate with written
1043 and oral comments. Similar to the national outreach, accommodation should be made to ensure that
1044 materials and translators are available for the range of languages spoken in the local community. The
1045 process should include a public comment period with a public docket, allowing for up to a 120-day notice
1046 period on a proposed study design and an opportunity to comment on the final. A truly participatory
1047 process should seek to engage a cross-section of the community. Local and regional outreach efforts to
1048 engage the public should involve communicating with community-based groups, labor organizations,
1049 housing and tenant groups, the faith community, health care and medical offices, public health officials,
1050 local elected officials, school boards, parent-teacher associations, water utility districts and other entities
1051 in the community that have the ability to reach members of the community through their membership,
1052 patients, listservs, websites, newsletters, mailing lists, social networks, media, and other distribution
1053 mechanisms. In addition, notice of the opportunity to participate should be posted throughout the
1054 community wherever public notices are posted.

1055
1056 Since most participatory processes are self-selective, it is critical that the outreach and inclusion
1057 methodology eliminate the barriers to participation and ensure participants an opportunity to establish the
1058 framework and definitions of the problem(s) and the data necessary to capture it. To that end, the agency
1059 should hold workshops to collect the community perspective on the study design. The workshops should
1060 be held in venues that are accessible and comfortable to community members and should be scheduled so
1061 as to not conflict with community members' work schedules. Public comments should be transcribed and
1062 placed in the docket. For those community members who do not use computers, a toll-free number should
1063 be available for questions and a written transcript of the workshops and relevant materials should be made
1064 available at the local libraries. Local governments should provide assistance, as feasible, to enable
1065 effective representation of community members (e.g., provide cost-free childcare, assist with
1066 transportation to and from the meeting, etc.).

1067
1068 The number of workshops should be determined based on the size of the community. No less than two
1069 workshops should be held in communities with populations less than 25,000, and additional workshops
1070 should be scheduled for every 100,000 population up to a maximum of ten workshops.

1071
1072

1073 **7. Standardization & Integration**

1074
1075 To ensure that information can be collected, exchanged, and interpreted by all interested parties, agencies
1076 conducting surveillance and monitoring activities must identify data, collection methods, and information
1077 system standards. Adopting and implementing standards for content, format, collection, transport, and
1078 interpretation of data will strengthen the ability of governmental agencies to exchange information needed
1079 for assessing environmental threats and designing effective interventions.

1080
1081 The work group recommends that EPA, CDC, and other agencies conducting ongoing surveillance and
1082 monitoring programs evaluate the feasibility of developing a clearinghouse of standardized methods for
1083 data collection and interpretation. CDC should also evaluate the possibility of providing a "Community of
1084 Practice" (CoP) forum for this community. One suggestion is to build upon the existing Public Health
1085 Information Network (PHIN), to enhance cooperation, standardization, and integration of environmental
1086 sampling and analytical methods, biomonitoring approaches, and other methods associated with exposure
1087 monitoring. Suggested methods to implement a CoP include electronic collaboration tools, such as
1088 message boards, listservs, chat rooms, webinars, and shared electronic workspaces.

1089

1090 The clearinghouse and CoP should be established within 3 years of the publication of this report.

1091

1092 **8. Balancing Public Access to Data with Confidentiality**

1093

1094 Recent efforts by the federal government to protect confidentiality for individual respondents have been
1095 very successful. Language can be found in the Health Insurance Portability and Accountability Act
1096 (HIPAA), the Confidential Information Protection and Statistical Efficiency Act (CIPSEA), and other
1097 acts. An unfortunate result is that local datasets on chemical exposure are frequently prevented from being
1098 released, since they could result in possible disclosure of personally identifiable information.

1099

1100 A second method used by the federal government to protect the confidentiality of data is to mask the
1101 datasets by either swapping some responses or adding “noise.” In both cases the trade-off for
1102 confidentiality is reduced data quality. So even when data are released, their accuracy may have been
1103 reduced, limiting their utility for local analyses.

1104

1105 **(a) OMB should sponsor a National Academy of Sciences (NAS) study to explicitly address the**
1106 **balance between confidentiality and data quality, especially for local analyses.**

1107

1108 It is important to recognize that maintaining data quality, especially for local analyses, is an important
1109 consideration that must be balanced with protection of confidentiality. HIPAA and CIPSEA restrict
1110 access to data to protect confidentiality to individuals. Masking data allows for data releases but of
1111 reduced quality. The NAS should assess the impact of data masking and identify how these actions can be
1112 balanced so that they assist analyses of chemical issues, particularly at the local level.

1113

1114 The NAS should also investigate the similar balance between protecting confidential business information
1115 and releasing data on possible chemical exposures. For example, providing more detail on toxic releases
1116 may conflict with protecting confidential intellectual property. The NAS should take account of product
1117 development life cycle and volume of product releases. It would also be important to consider the trade-
1118 off mandated by other international organizations since industry will have to respond to the combined sets
1119 of requirements in all locations where they operate.

1120

1121 This study should be initiated within three years.

1122

1123 **(b) Respondents should have access to data collected on them.**

1124

1125 Study respondents should be offered the option to receive the results of personal biomonitoring and
1126 physical samples collected from their property. These data should be accompanied by explanations aimed
1127 at a layman that provide context for the exposure measurements.

1128

1129 **(c) ATSDR or other governmental agencies should serve as a clearinghouse for quality local studies**
1130 **of chemical exposure.**

1131

1132 Such a clearinghouse would greatly assist local efforts to understand their exposures and to recognize if
1133 those are unusual compared to similar locales elsewhere. While ATSDR would not be expected to
1134 evaluate the quality of the local studies, the clearinghouse should provide standardized information that
1135 would allow potential users to judge the applicability of the data. Examples of documentation that should
1136 be required for inclusion of a local study in the clearinghouse include:

1137

- Statistical sample design;
- Sample size;
- List of chemicals tested for;

1138

1139

- 1140 • Physical analytic methods;
- 1141 • Basic findings;
- 1142 • Links to publications or a summary of findings; and
- 1143 • Contact person information.

1144
1145

1146 **Additional Priority Considerations**

1147

1148 As noted in the Vision discussion above, changes in research policy and funding practice appear to be
1149 essential to adequately address and resolve “hypothesis-generating” information resulting from expanded
1150 biomonitoring. The members of the Monitoring work group are not experts in the area of national
1151 research program design, and do not feel that they have the requisite knowledge and experience to
1152 recommend specific changes in this area – but the need is abundantly clear. The work group would
1153 recommend that the National Academy of Sciences, including the Institute of Medicine, be specifically
1154 charged with evaluating and providing recommendations to address two specific questions:

1155

1156 *(a) What approach should be taken to best identify plausible and pertinent hypotheses among the results*
1157 *of hypothesis-generating efforts and determine which hypotheses merit further study in order to*
1158 *obtain more definitive information on causal relationships?*

1159

1160 The criteria will clearly go beyond epidemiologic considerations and will need to address practical issues.
1161 For example, there may be little point in pursuing additional studies on outmoded chemicals or chemicals
1162 which have been discontinued for other reasons, or in expending resources on detailed study when
1163 containment may be a preferred option.

1164

1165 *(b) What changes in national research policy would assure that hypothesis-testing research will be*
1166 *undertaken when necessary and appropriate?*

1167

1168 Many models are possible, and it would seem appropriate to consider possible major changes in practice,
1169 policy, and/or funding to meet this need, rather than considering only minor adjustments to the current,
1170 predominantly academic model.

1171

1172

1173 **V. Conclusion**

1174

1175 This report presents the Monitoring work group’s findings and recommendations regarding the United
1176 States’ approach to monitoring and surveillance for the purpose of protecting the public from harmful
1177 chemical exposures. The work group approached this report by addressing issues along a temporal
1178 continuum, focusing on chemical use and release, environmental monitoring, biomonitoring, and health
1179 outcomes monitoring. This report characterizes the key components along this continuum; the major
1180 strengths and limitations that exist within each topic; the work group’s vision of a successful monitoring
1181 system; and actionable recommendations to achieve that vision.

1182

1183 The work group acknowledges several key themes that arise in its report: comprehensiveness,
1184 integration, prioritization, and action. The recommendations strive to expand and link the nation’s many
1185 existing efforts to monitor chemicals and public health, and to leverage existing infrastructure,
1186 information, and resources whenever possible. The work group recognizes that challenges and in some
1187 cases controversies are associated with issues discussed in this report, and members believe that this
1188 report reflects their support of the values of fairness, accuracy, prevention, and the protection of
1189 vulnerable populations. As suggested by the recommendations in this report, achieving the work group’s

1190 vision will take a concerted effort by experts in numerous organizations, both within and external to the
1191 government. The work group hopes that this report will move the United States toward an effective,
1192 coordinated monitoring system for public health and chemical exposures.
1193

DRAFT

References

- 1194
1195
1196 Acquavella, J., Alexander, B., Mandel, J., & Gustin, C. (2006). The farm family exposure study:
1197 Acquavella et al. respond. *Environmental Health Perspectives*, 114:A633-A634.
1198
1199 [ATSDR] Agency for Toxic Substances and Disease Registry. (2009). *Glossary of terms*. Retrieved from
1200 <http://www.atsdr.cdc.gov/glossary.html>.
1201
1202 Blount, B., Silva, M., Caudill, S., Needham, L., Pirkle, J., Sampson, E., Lucier, G., Jackson, R., & Brock,
1203 J. (2000). Levels of seven urinary phthalate metabolites in a human reference population.
1204 *Environmental Health Perspectives*, 108(10), 979-982.
1205
1206 [CDC] Centers for Disease Control and Prevention (2008). *Division of laboratory sciences*. Retrieved
1207 from <http://www.cdc.gov/nceh/dls/pdf/DLSBrochure.pdf>.
1208
1209 [CDC] Centers for Disease Control and Prevention. (2009). *National environmental public health*
1210 *tracking glossary*. Retrieved from <http://www.cdc.gov/nceh/tracking/lib/glossary.htm>.
1211
1212 [CDC] Centers for Disease Control and Prevention. (2010a). *National report on human exposure to*
1213 *environmental chemicals*. Retrieved from <http://www.cdc.gov/exposurereport>.
1214
1215 [CDC] Centers for Disease Control and Prevention. (2010b). *National vital statistics system*. Retrieved
1216 from <http://www.cdc.gov/nchs/nvss.htm>.
1217
1218 [EPA] United States Environmental Protection Agency. (2006). *Terms of environment: Glossary,*
1219 *abbreviations and acronyms*. Retrieved from <http://www.epa.gov/OCEPATERMS>.
1220
1221 [EPA] United States Environmental Protection Agency. (2008a). *EPA's 2008 report on the environment*.
1222 Retrieved from http://oaspub.epa.gov/eims/eimscomm.getfile?p_download_id=485027.
1223
1224 [EPA] United States Environmental Protection Agency. (2008b). *About the national emission inventory*
1225 *database*. Retrieved from <http://www.epa.gov/oar/data/neidb.html>.
1226
1227 [EPA] United States Environmental Protection Agency. (2008c). *2006 inventory update reporting: Data*
1228 *summary*. Retrieved from http://www.epa.gov/iur/pubs/2006_data_summary.pdf.
1229
1230 [EPA] U.S. Environmental Protection Agency. (2008d). *Ambient air monitoring strategy for state, local,*
1231 *and tribal air agencies*. Retrieved from
1232 <http://www.epa.gov/ttnamti1/files/ambient/monitorstrat/AAMS%20for%20SLTs%20%20-%20FINAL%20Dec%202008.pdf>.
1233
1234
1235 [EPA] United States Environmental Protection Agency. (2009). *National pollutant discharge elimination*
1236 *system (NPDES)*. Retrieved from <http://cfpub.epa.gov/npdes>.
1237
1238 [EPA] United States Environmental Protection Agency. (2010a). *What information must be submitted*
1239 *about new chemical substances?*. Retrieved from
1240 <http://www.epa.gov/opptintr/newchems/pubs/whatinfo.htm>.
1241
1242 [EPA] United States Environmental Protection Agency. (2010b). *Pesticide product information system*
1243 *(PPIS)*. Retrieved from <http://www.epa.gov/pesticides/PPISdata/index.html>.
1244

- 1245 [EPA] United States Environmental Protection Agency. (2010c). *What is the Toxics Release Inventory*
1246 *TRI) program*. Retrieved from <http://www.epa.gov/tri/triprogram/whatis.htm>.
1247
- 1248 [EPA] United States Environmental Protection Agency. (2010d). *Who must report?*. Retrieved from
1249 <http://www.epa.gov/tri/threshold/ThresholdDetermination.htm>.
1250
- 1251 [EPA] United States Environmental Protection Agency. (2010e). *TRI current data*. Retrieved from
1252 http://www.epa.gov/tri/tridata/current_data/index.html.
1253
- 1254 [EPA] United States Environmental Protection Agency. (2010f). *National contaminant occurrence*
1255 *database (NCOD)*. Retrieved from
1256 <http://water.epa.gov/scitech/datait/databases/drink/ncod/databases-index.cfm>.
1257
- 1258 [EPA] United States Environmental Protection Agency. (2010g). *Healthy buildings, healthy people: A*
1259 *vision for the 21st century*. Retrieved from <http://www.epa.gov/iaq/hbhp/index.html>.
1260
- 1261 [FDA] United States Food and Drug Administration. (2009). *Total diet study - analytes and analytical*
1262 *methods*. Retrieved from
1263 [http://www.fda.gov/Food/FoodSafety/FoodContaminantsAdulteration/TotalDietStudy/ucm18464](http://www.fda.gov/Food/FoodSafety/FoodContaminantsAdulteration/TotalDietStudy/ucm184646.htm)
1264 [6.htm](http://www.fda.gov/Food/FoodSafety/FoodContaminantsAdulteration/TotalDietStudy/ucm184646.htm)
1265
- 1266 Karkkeinen, B. (2001). Information as environmental regulation: TRI and performance benchmarking,
1267 precursor to a new paradigm? *Georgetown Law Journal*, 89, 257–370.
1268
- 1269 National Institutes of Health. (2010). *Surveillance epidemiology and end results*. Retrieved from
1270 <http://seer.cancer.gov>.
1271
- 1272 Silva, M., Barr, D., Reidy, J., Malek, N., Hodge, C., Caudill, S., Brock, J., Needham, L., & Calafat, A.
1273 (2004). Urinary levels of seven phthalate metabolites in the U.S. population from the national
1274 health and nutrition examination survey (NHANES) 1999–2000. *Environmental Health*
1275 *Perspectives*, 112(3), 331-338.
1276
- 1277 Stephan, M. (2002). Environmental information disclosure programs: They work, but why? *Social*
1278 *Science Quarterly*, 83(1), 190-205.
1279
- 1280 Toxic Substances Control Act, 15 U.S.C. § 2601 et seq. (1976).

Appendix A. Monitoring Work Group Final Charge

Monitoring Work Group: *facilitating the collection, analysis and interpretation of information on chemicals, including their sources, uses, exposures, and associated health outcomes.*

The prevention and control of adverse health outcomes related to chemical exposures requires the ongoing collection, integration, analysis, and interpretation of data about chemicals, including their sources, uses, exposures, and associated health outcomes. Ongoing surveillance also provides an opportunity to evaluate the effectiveness of intervention strategies. Many federal, state, local, and tribal government bodies currently collect relevant data.

This working group will analyze current surveillance and data collection activities and recommend actions to fill data gaps, better utilize existing data, and improve coordination among the many organizations collecting relevant information. The group will address monitoring of chemicals in both human tissues (biomonitoring) and environmental media, including soil, air, water, consumer products, food, and in key built environments (e.g. schools and homes). Further, the group will address options for enhancing the interpretability of exposure information for the purpose of analyzing associations with health outcome data. The group will work together with members of the chemical emergencies work group to develop recommendations related to monitoring acute events.

Appendix B. Monitoring Work Group Roster

Chair

John Balbus, National Institute of Environmental Health Sciences

Members

Henry Anderson, Wisconsin Division of Public Health
Herb Buxton, U.S. Geological Survey
Alison Edwards, U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition
Jay Feldman, Beyond Pesticides
Roy Fortmann, U.S. Environmental Protection Agency
Daniel Goldstein, Monsanto
Nancy John, Cherokee Nation
Charlotte L. Keys, Jesus People Against Pollution
Megan Latshaw, Association of Public Health Laboratories
Sam LeFevre, Utah Department of Health
Dean Lillquist, U.S. Occupational Safety and Health Administration
David Marker, Westat
John Osterloh, Centers of Disease Control and Prevention, National Center for Environmental Health
Jennifer Parker, Centers of Disease Control and Prevention, National Center for Health Statistics
Sharyle Patton, Commonweal
Karen Pierce, Bayview Hunters Point Community Advocates
Ruthann Rudel, Silent Spring Institute
Martha Stanbury, Michigan Department of Community Health
Trey Thomas, Consumer Product Safety Commission
Richard Van Frank, Improving Kids' Environment
Steve Whittaker, Public Health - Seattle & King County
Alan Woolf, Children's Hospital, Boston

Support

Michael McGeehin, NCEH/ATSDR *senior liaison*
Kathy Grant, RESOLVE *facilitator*
Jenny Van Skiver, NCEH/ATSDR *staff*

Appendix C. Acronyms

APHA: American Public Health Association
APHL: Association of Public Health Laboratories
ASTHO: Association of State and Territorial Health Officials
ATSDR: Agency for Toxic Substances and Disease Registry
ATUS: American Time Use Survey
BRFSS: Behavioral Risk Factor Surveillance Survey
CDC: Centers for Disease Control and Prevention
CBI: Confidential Business Information
CHDI: Community Health Data Initiative
CIPSEA: Confidential Information Protection and Statistical Efficiency Act
CoP: Community of Practice
CPSC: Consumer Product Safety Commission
CPSIA: Consumer Product Safety Improvement Act
CSN: Chemical Speciation Network
CSTE: Council of State and Territorial Epidemiologists
DOE: United States Department of Energy
ECHA: European Chemicals Agency
EPA: United States Environmental Protection Agency
EPCRA: Emergency Planning and Community Right-to-Know Act
EPHT: Environmental Public Health Tracking
FDA: United States Food and Drug Administration
FRMs: Federal Reference Methods
FEMs: Federal Equivalent Methods
HANES: Health and Nutrition Examination Survey (see also, NHANES)
HAPs: Hazardous Air Pollutants
HHS: United States Department of Health and Human Services
HIPAA: Health Insurance Portability and Accountability Act
HUD: United States Department of Housing and Urban Development
IARC: International Agency for Research on Cancer
IMPROVE: Interagency Monitoring of Protected Visual Environments
NATTS: National Air Toxics Trends Stations
NAAQS: National Ambient Air Quality Standards
NACCHO: National Association of County and City Health Officials
NAS: National Academy of Sciences
NAWQA: National Water Quality Assessment
NCEH: CDC's National Center for Environmental Health
NCOD: National Contaminant Occurrence Database
NEI: National Emissions Inventory
NHANES: National Health and Nutrition Examination Survey
NIH: National Institutes of Health
NIOSH: National Institute for Occupational Safety and Health
NPDES: National Pollutants Discharge Elimination System
NTP: National Toxicology Program
NWIS: National Water Information System
OMB: United States Office of Management and Budget
PAMS: Photochemical Assessment Monitoring Station
PHIN: Public Health Information Network
PMN: Premanufacture notice
POTW: Publicly Owned Treatment Works

PPIS: Pesticide Product Information System

REACH: Registration, Evaluation, Authorisation and Restriction of Chemicals

RfD: Reference dose

SDWA: Safe Drinking Water Act

SEER: Surveillance, Epidemiology and End Results

SIC: Standard Industrial Classification

SLAMS: State and Local Air Monitoring Stations

TSCA: Toxic Substances Control Act

TRI: Toxics Release Inventory

TWA: Time-weighted average

USGS: United States Geological Survey

DRAFT